In our study of patients with resistant hypertension, we have shown that vascular function improves with the use of spironolactone, a mineralocorticoid receptor antagonist. Spironolactone has also been shown to reduce urinary protein loss in patients with chronic kidney disease. We are looking for men and women, ages 19-65, with Stage III CKD, non-diabetic or who have controlled diabetes, and who are not currently taking spironolactone or amiloride. The study lasts 16 weeks, with six visits, and compensation and parking will be provided for all six visits. If interested, please contact Cassidy Clevenger at (205) 934-6745.